EP Patent

EP3486234A1 — Aryl- or heteroaryl-substituted benzene compounds

Assigned to Epizyme Inc · Expires 2019-05-22 · 7y expired

What this patent protects

The present invention relates to aryl- or heteroaryl-substituted benzene compounds (I) for use in treating a cell proliferative disorder.

USPTO Abstract

The present invention relates to aryl- or heteroaryl-substituted benzene compounds (I) for use in treating a cell proliferative disorder.

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: EP3486234A1
Jurisdiction: EP
Classification: —
Expires: 2019-05-22
Drug substance claim: No
Drug product claim: No
Assignee: Epizyme Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.